Effect of obesity on pharmacokinetics and biologic effect of interferon-α in hepatitis C

被引：45

作者：

Lam N.P. ^{[1
]}

Pitrak D. ^{[1
]}

Speralakis R. ^{[1
]}

Lau A.H. ^{[1
]}

Wiley T.E. ^{[1
]}

Layden T.J. ^{[1
]}

机构：

[1] Department of Pharmacy Practice, College of Pharmacy, Chicago, IL 60612

来源：

Digestive Diseases and Sciences | 1997年 / 42卷 / 1期

关键词：

2'; 5'-oligoadenylate synthetase; chronic hepatitis C; histologic activity index; interferon-α; obesity;

D O I：

10.1023/A:1018865928308

中图分类号：

学科分类号：

摘要：

To examine potential adverse effects of obesity in reducing the response to interferon-α (IFN-α) in chronic hepatitis C (HCV), IFN-α and HCV RNA levels in serum and the 2',5'-oligoadenylate synthetase (2-5 OAS) levels in peripheral blood mononuclear cells (PBMC) were compared between six obese and five nonobese patients before and after a single, 10 mIU dose of IFN-α(2b). There were no differences in the mean histologic activity index between the two groups. The maximal IFN concentration and the area under the serum IFN concentration-time curve were higher in nonobese patients. These two parameters were inversely correlated with body weight and body surface area. No differences were found in the mean reduction in HCV RNA levels between the two groups following IFN-α. The maximal 2-5 OAS level after treatment divided by the pretreatment 2-5 OAS level (2-5 OAS response ratio) was greater in the nonobese patients, suggesting stronger biologic response upon exposure to exogenous IFN-α in nonobese patients.

引用

页码：178 / 185

页数：7

共 41 条

[21]

Heathcote E.J., Kim Y.I., Yom C.K., Lebrocq J., Read S.E., Interferon-associated lymphocyte 2′5′-oligoadenylate synthetase in acute and chronic viral hepatitis, Hepatology, 9, pp. 105-109, (1989)

[22]

Grossberg S.E., Taylor J.L., Siebenlist R.E., Jameson P., Biological and immunological assays of human interferons, Manual of Clinical Laboratory Immunology, pp. 295-299, (1986)

[23]

Gretch D., Lee W., Corey L., Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory, J Clin Microbiol, 30, pp. 2145-2149, (1992)

[24]

Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y., Mayami M., Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infections sources, J Gen Virol, 73, pp. 673-679, (1992)

[25]

Gibaldi M., Perrier D., Pharmacokinetics, (1982)

[26]

Wong D.K.H., Yim C., Naylor C.D., Chen E., Sherman M., Vas S., Wanless I.R., Read S., Li H., Heathcote E.J., Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population, Gastroenterology, 108, pp. 165-171, (1995)

[27]

Abernethy D.R., Greenblatt D.J., Drug disposition in obese humans: An update, Clin Pharmacokinet, 11, pp. 199-231, (1986)

[28]

Bauer L.A., Drew Edwards W.A., Patchen Dellinger E., Simmonowitz D.A., Influence of weight on aminoglycosides pharmacokinetics in normal weight and morbidly obese patients, Eur J Clin Pharmacol, 24, pp. 643-647, (1983)

[29]

Lind M.J., Margison J.M., Cerny T., Thatcher N., Wilkinson P.M., Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution, Cancer Chemother Pharmacol, 25, pp. 139-142, (1989)

[30]

Bauer L.A., Wareing-Tran C., Drew Edwards W.A., Raisys V., Ferreri L., Jack R., Dellinger E.P., Simonowitz D., Cimetidine clearance in the obese, Clin Pharmacol Ther, 37, pp. 425-430, (1985)

← 1 2 3 4 5 →